Sarepta declines as worries about future gene therapy findings surface.
Sarepta Therapeutics shares slumped 11% on Friday as some analysts voiced concerns…
Sarepta’s gene therapy for rare muscular dystrophy in some children has received US FDA approval.
The U.S. drug regulator on Thursday granted accelerated approval to Sarepta Therapeutics'…
Krystal Biotech’s skin condition gene therapy has received U.S. FDA approval.
The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's…
Cost-effective gene therapy from Vertex/CRISPR is $1.9 million, according to the price review group.
Vertex Pharmaceuticals Inc and CRISPR Therapeutics AG's one-dose gene editing therapy for…